We report outcomes for 44 children who underwent stem cell transplantation (SCT) for refractory AML in the UK between 2000 and 2012. Median age at SCT was 11.5 years. Twenty-three patients had primary refractory and 21 relapsed refractory AML. Refractory disease was confirmed by cytogenetics/molecular genetics in 24 cases. Median follow-up of the whole cohort is 6.8 years (2.1-14.9 years). Thirty patients (68%) achieved a CR following SCT. Transplant-related mortality at 1 year was 18%. Acute GVHD incidence was 52% (grade ⩾ III 19%), chronic 7%. Relapse was the major cause of treatment failure and occurred in 32% of patients at a median of 61 days post SCT. Five-year overall survival and leukemia-free survival (LFS) were 43% (95% CI 31-61%). All patients with favorable cytogenetics (n = 6) are alive in CR. Outcomes in patients with primary refractory disease were equivalent to those with relapsed refractory AML. Blast percentage ⩽ 30% in the BM pre-SCT, myeloablative conditioning and acute GVHD proved to be favorable prognostic features. We could stratify patients according to age ⩾ 10 years and 430% blasts in BM pre-SCT. Patients with none/one of these risk factors were highly salvageable (5 years LFS 53%) whereas those with both factors had a very poor prognosis (5 years LFS 10%). This may facilitate decision making on whether it is appropriate to consider transplant in such patients.
INTRODUCTION
Five to 10% of children with de novo AML and as many as 23% of patients with relapsed AML have a refractory disease, defined as failure to achieve a morphological remission after two courses of chemotherapy. [1] [2] [3] [4] Since the incidence of AML in the pediatric population in the UK is 70 cases per year, between 8 and 12 children per year are expected to present with refractory AML in the country. Historically, the prognosis for this subgroup of patients has been dismal, with recent cooperative trials suggesting an overall survival (OS) of 22 and 14% for primary refractory and relapsed refractory pediatric AML. 3, 4 The best treatment for these patients is yet to be identified. Allogeneic hematopoietic stem cell transplantation (SCT) represents the standard of care for high-risk frontline or relapsed AML. [5] [6] [7] However, data on the outcomes of patients undergoing SCT for refractory disease are scanty. Different approaches and non-uniform cohorts have yielded widely varying results, with survival rates of 0-35% and transplant-related mortality (TRM) as high as 40%. 4, 9, [8] [9] [10] [11] [12] [13] [14] Specifically, for children not in remission at transplant, a total of 160 patients have been reported in four different papers. 4, 8, 10, 14 Three of these papers (including two prospective national studies) document a 0% long-term OS for children with active disease at SCT. 4, 10, 14 On the contrary, Bunin et al. 8 documented a leukemiafree survival (LFS) of 12% for children with primary refractory AML and of 20% for relapsed refractory patients. Moreover, in a registry analysis combining data from adults and children by the CIBMTR on 1428 AML patients in non-remission at transplant, 19% OS has been reported. 9 In this context, blasts percentage at transplant, mismatched or unrelated donor, poor performance status and poor-risk cytogenetics have been proposed as possible combined risk factors for poorer outcome.
Given the dismal prognosis for refractory AML, a recent review discourages offering SCT to adults with blast percentage 425% in the bone marrow (BM) at transplant. 15 Recommendations for treatment in children with a similar situation are not available. With no significant alternative treatment options for most of these patients, more data are required in order to make an informed and patient tailored decision. This multicenter, retrospective study aimed to assess the outcome and identify predictive factors for children receiving their first SCT for primary refractory or relapsed refractory AML with active disease at SCT.
MATERIALS AND METHODS Patients
Patients aged 0-18 undergoing a first allogeneic SCT for primary refractory or relapsed, refractory AML in 1 of the 13 pediatric transplant Centers in the UK between 2000 and 2012 and reported to the British Society for Blood and Bone Marrow Transplantation (BSBMT) were eligible for this study if they had active disease documented within 2 weeks from the start of the conditioning regimen. Patients with AML FAB M3 and juvenile myelomonocytic leukemia were excluded from the study. Refractory disease was defined as 45% blasts in BM either morphologically or by cytogenetics or molecular methods or proven extramedullary (EM) disease after ⩾ 2 courses of induction/re-induction chemotherapy.
Primary induction failure was defined as 45% blasts in BM either morphologically or by cytogenetics or molecular methods at the end of the second induction course.
CR was defined by BM with normal hematopoiesis and o5% blasts morphologically.
Cytogenetic risk was classified according to WHO 2008 and integrated with specific pediatric recommendations. 6, 16 Source data were verified to confirm diagnosis of refractory disease in all patients by reviewing the morphology and cytogenetics/molecular results at significant time points, but no centralized morphology review of the pre-SCT bone marrow aspirates was performed.
Consent for data to be registered on the BSBMT Registry for outcome and research analysis was obtained at the time of transplantation, in line with EBMT directives.
Transplant procedure HLA compatibility with an adult related or unrelated donor was defined by high/medium resolution typing for HLA-A, -B, -C, -DR, -DQ loci. HLA compatibility with an unrelated cord was defined as by high/medium resolution typing for HLA-A, -B, -DR loci. HLA compatibility with a sibling donor was defined by low-resolution typing for HLA-A, -B, -C, -DR, -DQ. Donors were defined as a HLA identical sibling if they inherited the same parental haplotypes as their recipients. Donor-recipient pairs were defined as HLA matched (MD) if they were 10/10 (adult donor) or 6/6 (cord) and HLA mismatched (MMD) otherwise.
Conditioning regimens were defined as 'reduced intensity' according to the Champlin criteria, and myeloablative otherwise. 17 In brief, a conditioning regimen was considered myeloablative if causing irreversible cytopenia without stem cell rescue, and at reduced intensity if resulting in reversible myelosuppression associated with low rates of non-hematologic toxicity. 17 
Study end points
The primary end point of the study was LFS at 5 years post SCT in children with primary refractory or relapsed refractory AML transplanted in non-remission. LFS was defined as the time from transplantation to relapse or death from any cause, whichever comes first. Secondary end points included the incidence of acute and chronic GVHD, relapse rate, TRM and 5 years OS. TRM was defined as any death occurring in CR; OS was defined as the time from SCT to death, irrespective of the cause.
Statistical analysis
Patient data were collected through the BSBMT database and verified with each center. Data were checked for consistency and final analysis was performed by means of the statistical software Stata (StataCorp. 2015. Stata Statistical Software: Release 14, College Station, TX: StataCorp LP) and R. Follow-up was updated as of 1 January 2016. Descriptive analyses results are reported as medians and ranges. Kaplan-Meier estimators and confidence intervals were used to estimate LFS and OS and the Log rank test (discreet variables) and Cox regression were used for comparison. 18 Patients were censored at last follow-up if no events occurred. The cumulative incidence of relapse and TRM were estimated allowing for competing risks by the Fine-Grey method. 19 The Cox proportional hazard regression models were used to evaluate the impact on relapse, LFS and OS of the following variables: age, cytogenetic risk group, primary vs relapsed refractory, percentage of blasts in the BM at SCT, conditioning regimen, donor type (matched vs mismatched), use of T-cell depletion, stem cell source and presence of acute and chronic GVHD. Confidence intervals are reported at the 95% and statistical tests were performed at the 0.05 level (two-sided).
RESULTS

Patients characteristics
Sixty-one patients were identified via the BSBMT registry as SCT recipients for refractory AML not in CR at SCT between 2000 and 2012. Two patients were excluded on the basis of the diagnosis of juvenile myelomonocytic leukemia, and 15 patients were excluded as data verification did not confirm the diagnosis of refractory AML. The remaining 44 patients, for whom source data verification confirmed refractory disease, were analyzed. Characteristics of the 44 patients who entered the study are summarized in Table 1 .
Overall, 16 (36%) were female, median age at diagnosis was 10.9 years (range 4 months to 17.5 years). Twenty-three patients were classified as affected by primary refractory AML and 21 as by relapsed refractory. Six patients had underlying myelodysplasia. One had a treatment-related AML post Wilms´tumor. Fourteen patients had adverse cytogenetic profiles, 24 standard risk and 6 patients had favorable cytogenetic characteristics. As expected, none of the patients with favorable cytogenetics had primary refractory disease, and this was the only statistically significant difference in the baseline characteristics between primary refractory and relapsed, refractory patients. At diagnosis, five patients had combined BM and EM involvement (one skin, one periorbital, one CNS, one zygoma, one unknown). The median number of treatment lines prior to SCT was 3 in the primary refractory and 2 in the relapsed, refractory group of patients. None of the patient was in remission at the beginning of the conditioning regimen pre-SCT. Specifically, 37 patients had 45% blasts in the BM by morphology (median blasts in the BM aspirate 23%, range 5-95%) of whom 19 had 45% blasts in the BM confirmed by cytogenetics or molecular techniques. Five patients had 45% blasts in the BM by cytogenetics only (median blasts 20%, range 7.5-81%) and two patients had isolated EM relapse (petrous bone diagnosed via histopathology and periorbital diagnosed via imaging) (see Supplementary Table S1 ).
Transplantation characteristics Transplant characteristics are summarized in Table 2 . Overall the median time from diagnosis to SCT was 197 days (range 74-1155 days (3y 2 m)). Median age at SCT was 11.5 years (range 7 months to 17 years and 9 months). Ten patients (23%) underwent a reduced intensity conditioning, in five cases because of comorbid conditions. Thirty-four patients (77%) received myeloablative preparative regimens (MAC). Specifically, 14 patients had TBI-based conditioning, 21 had Busulfan-based conditioning (with 8 patients receiving Bu-Cy-Mel), Treosulfanbased regimens were used in six patients and the remaining three had Fludarabine-based preparatory regimens. Thirty patients (68%) had a matched family (n = 15) or matched unrelated donor (n = 15). In vivo T-cell depletion was administered in 24 patients (55%). In detail, 12 patients received Campath and 12 received antithymocyte globulin. Additionally, eight patients receiving PBSC from mismatched unrelated donors had ex vivo T-cell depletion. Forty-five percent of the patients received peripheral blood as a stem cell source, 41% BM and 14% cord blood. Overall, baseline transplant characteristics were not significantly different between relapsed refractory and primary refractory patients.
Post-transplant course Table 3 summarizes the post-transplant outcomes of our cohort. One patient died on day +10 (septic event) and one on day +14 (disease progression). Of the 42 evaluable patients, 39 achieved engraftment (93%). Median time to neutrophil engraftment was 15 days (range 10-42). Two patients showed relapse at engraftment (5%). Acute GvHD was reported in 23 patients (52%), and was severe in eight patients (19%). One patient experienced limited and two extensive chronic GvHD, overall incidence being 7%. GvHD was considered the cause of death in two patients in our cohort.
Outcome Nine patients died in CR from transplant-related causes (two GVHD related, one cardiac toxicity, one Aspergillus chest infection, one encephalitis, one CMV-related infection, one sepsis, one endocarditis, one adenovirus-related pneumonitis). Five of these eight patients died before day +100 post SCT. TRM at day +100 and day +365 was 11% (95% CI 4-23%) and 18% (95% CI 9-31%), respectively. Out of 44 patients, 30 (68%) achieved CR following SCT. Eighteen are alive in CR and the 5 years LFS in this cohort was 43% (95% CI 28-57%) with a median follow-up of 6 years and Table 4 for detailed tests of differences in outcomes.
SCT for pediatric refractory AML P O'Hare et al 9 months. Seventeen patients relapsed at a median time of 61 days post SCT (range 13-279) and all of them died of disease progression. One single patient who relapsed entered a further CR after subsequent treatment underwent a second SCT after which he relapsed again and died as a consequence of his disease progression. The cumulative incidence of relapse was 32% at 5 years (95% CI 19-46%).
Subgroup analysis
Relapse risk and non-relapse mortality were similar between patients with primary refractory and relapsed refractory disease ( Figure 1) . As a consequence, the 5-year LFS and OS for patients with primary refractory AML (43% (CI 22-62%) and 43% (CI 22-62%)) were superimposable to those for patients with relapsed refractory disease (43% (CI 22-62%) and 43% (CI 22-62%)) ( Figure 2) . Similarly, patients with unfavorable cytogenetics did not show a worse outcome than those with standard cytogenetics (cumulative incidence of relapse 29% vs 42%, P = 0.345). In contrast, none of the patients with favorable cytogenetic profile relapsed post transplant (Figure 3) , and their 5 years LFS was 67% (CI 19-90%), although this did not reach statistical significance because of the low patient number in this group (n = 6). Table 4 summarizes the analyzed prognostic factors for LFS, relapse incidence and non-relapse mortality rate in our cohort. Regression analysis showed that undergoing transplantation with blasts percentage higher than 30% in the BM predicted a significantly higher relapse risk (60% vs 15%, P = 0.004), whereas receiving a myeloablative procedure and developing acute GVHD influenced positively the outcome in our cohort of patients ( Figure 4a) . No other transplant-related characteristics (donor, stem cell source, T-cell depletion) impacted on long-term outcome. Patients ⩾ 10 years of age showed a trend towards increased transplant-related mortality (5% vs 29%, P = 0.05).
Combining the above risk factors, we were able to identify a group of children at very high risk of relapse. Indeed patients ⩾ 10 years of age with 430% blasts at SCT showed a significant worse outcome than the rest of our population, proving almost unsalvageable (LFS 10% vs 53%, P = 0.037, Figure 4b ).
DISCUSSION
Although SCT is often used to treat high-risk AML, its role in the context of chemo-refractory disease is still debated. 6 This study investigated the role of SCT in pediatric patients with refractory AML and prognostic features in this context. Our series shows that SCT can be curative in a significant number of children transplanted with active AML, with a 5-year LFS of 43%. In particular, we showed that younger patients with low disease burden at SCT achieved a remarkable LFS of 53%. Clearly, one major limitation of our study is that the nature of the registry precludes assessment of how many refractory AML cases were diagnosed in the study period in the UK, thus omitting the important information about how many patients were deemed unsuitable for SCT or died while waiting for SCT (we estimate that during the study period approximately 120 patients would have been diagnosed with refractory AML in the UK). This in turn results in a significant selection bias in our patient cohort.
Additionally, 18 patients in our cohort were diagnosed with refractory disease at SCT on the basis of morphological evaluation of the BM only, without molecular or cytogenetic confirmation. While morphological evaluation involves a degree of subjectivity, in this study the incidence of relapse among patients who were diagnosed as refractory based on morphology only was not 16 and Creutzig et al. 6 A full color version of this figure is available at the Bone Marrow Transplantation journal online. Abbreviations: BM = bone marrow; CB = cord blood; MAC = myeloablative conditioning; MD = matched donor; MMD = mismatched donor; RIC = reduced intensity conditioning; SCT = stem cell transplantation.
SCT for pediatric refractory AML P O'Hare et al statistically different from that of patients with a molecular/ cytogenetic confirmation (relapse incidence 53% vs 30%, P = 0.1, CI 0.8-6.5).
In spite of these possible biases, our data demonstrate remarkably good outcomes in the highly selected group of children with refractory AML who went on to SCT, which appear to be better than the published data, mostly from adult studies. Jabbour et al. 13 reported a 3-year DFS of 35% for adult patients undergoing SCT for primary refractory disease with a median percentage of blasts in the BM of 19% pre-SCT. Duval et al. 9 reported a large series of adult and pediatric patients receiving SCT after a myeloablative procedure for refractory AML in nonremission, and found, as in our study, that there was no difference in outcomes between patients with primary refractory and relapsed, refractory disease. In this group of patients, OS was lower than in our cohort (19% @ 3 years) and TRM higher (39% @ 1 year), possibly reflecting both the earlier study period (o 2004) and the effect of MAC on older patients (median age 38). Likewise Hemmati et al. 12 reported a 5-year DFS of 26% in 131 adults transplanted with refractory AML, and confirmed the favorable predictive role of lower blast count at SCT and acute GVHD. Interestingly, two prospective studies documented no survivors among patients with active disease at SCT, but only 13 such cases between both studies were reported, making any further comparison difficult. 4, 14 The available literature does not support specific transplant strategies for these patients in terms of conditioning regimens, donor choices, stem cell sources. The size of our cohort precludes definitive evaluations but our data suggest that MAC may improve outcomes compared with reduced intensity conditioning (5 years LFS 50% vs 20%, Po 0.05). Our cohort size was not large enough to determine whether this was restricted to patients who received TBI-based conditioning. Importantly, MAC was well tolerated in children below the age of 10, whereas older patients showed a higher TRM, particularly in patients with high disease burden, in keeping with published data. 8 Our data enable us to stratify patients according to their age and percentage of blasts prior to SCT (see Figure 4b ). This may assist clinicians in their decision as to whether it is appropriate to transplant children with refractory AML. Patients with none or one of these risk factors appear highly salvageable with SCT with an LFS of 53%. SCT seems to be of limited benefit for patients ⩾ 10 years old with 430% blasts in the marrow pre-SCT. In our cohort, only 1 of 10 children with these characteristics was salvageable. These patients should probably be counseled for phase 1 studies with targeted treatments whenever available, with the attempt of reducing the disease burden, becoming eligible for SCT if a response is obtained.
Our study suggests that GVHD post SCT was associated with reduced relapse risk (45% vs 17%, P = 0.05; Figure 4a ). The study of Hemmati et al. 12 found a similar correlation. There might therefore be a role in applying strategies to enhance the GVL effect as part of the treatment in patients with refractory disease. Given the early timing of post SCT relapse (median of 61 days in our cohort), those strategies might mostly rely on early immunosuppression withdrawal, on the use of KIR mismatched donors or on specific transplant modalities (e.g. cord blood transplantation omitting serotherapy as reported by Chiesa et al. 20 ). In our cohort stem cell source, T-cell depletion as well as the degree of donor matching did not show any prognostic impact on the outcomes, possibly due to the limited numbers of available patients. In terms of disease characteristics, while primary refractory and relapsed refractory disease shared a common outcome within our cohort, cytogenetics may be important as none of the six patients with favorable cytogenetics relapsed and 29% of the 14 patients with unfavorable cytogenetics did. While the limited number of patients in our cohort does not allow for statistical significance, these numbers hint at an impact of disease characteristics on the final outcome.
Within the limitations of a retrospective registry study, our data demonstrate that a significant proportion of children with active refractory AML is curable by SCT, particularly those with favorable cytogenetics, those below the age of 10 and with less than 30% blasts in the BM at SCT. This study also suggests that myeloablative conditioning regimen as well as GVL enhancing strategies might be beneficial in this context. According to our data, transplant does not seem to offer a significant chance of cure for patients above 10 years of age and with blasts 430% in the BM. This group of children should therefore be carefully evaluated for either phase 1 studies/novel treatment or palliative care according to their clinical status and the family inclination. 
